阿替利珠单抗或化疗作为小细胞肺癌二线治疗的随机非比较II期研究:IFCT-1603试验结果
该随机II期试验将一线铂-依托泊苷化疗后进展的小细胞肺癌患者按2:1随机分配至阿替利珠单抗组(1200 mg静脉注射,每3周一次)或常规化疗组,主要终点为6周客观缓解率。阿替利珠单抗组6周客观缓解率为2.3%(95%CI:0.0-6.8),化疗组为10%;中位无进展生存期分别为1.4个月和4.3个月;中位总生存期分别为9.5个月和8.7个月(校正HR 0.84,95%CI:0.45-1.58;P=0.60)。阿替利珠单抗单药在复发小细胞肺癌中未显示出显著疗效,未观察到非预期安全性问题。
要点
- 阿替利珠单抗组6周客观缓解率为2.3%(95%CI:0.0-6.8),化疗组为10%。
- 中位无进展生存期阿替利珠单抗组1.4个月(95%CI:1.2-1.5),化疗组4.3个月(95%CI:1.5-5.9)。
- 中位总生存期两组无显著差异(校正HR 0.84,95%CI:0.45-1.58;P=0.60)。
核心结论
- 阿替利珠单抗单药在复发小细胞肺癌中未能显示出显著疗效。
- 未观察到非预期的安全性问题。
研究设计与样本
- 随机非比较II期试验,患者按2:1随机分配至阿替利珠单抗组或常规化疗组。
- 阿替利珠单抗组给药方案为1200 mg静脉注射,每3周一次,直至进展或不可接受毒性。
- 化疗组接受最多6个周期的拓扑替康或初始化疗再诱导。
- 患者未根据PD-L1组织表达进行筛选。
- 主要终点为6周客观缓解率,采用两阶段设计及O'Brien-Fleming停止规则。
主要发现
- 共73例患者随机化(阿替利珠单抗组n=49;化疗组n=24)。
- 6周时,43例可评估阿替利珠单抗患者中1例达到客观缓解(2.3%,95%CI:0.0-6.8),另8例疾病稳定(疾病控制率20.9%,95%CI:8.8-33.1)。
- 20例可评估化疗患者中,10%达到客观缓解(疾病控制率65%)。
- 中位无进展生存期阿替利珠单抗组为1.4个月(95%CI:1.2-1.5),化疗组为4.3个月(95%CI:1.5-5.9)。
- 中位总生存期阿替利珠单抗组9.5个月 vs 化疗组8.7个月(校正HR 0.84,95%CI:0.45-1.58;P=0.60),两组无显著差异。
关键数值与推荐
- 主要终点6周客观缓解率:阿替利珠单抗组2.3%(95%CI:0.0-6.8) vs 化疗组10%。
- 6周疾病控制率:阿替利珠单抗组20.9%(95%CI:8.8-33.1) vs 化疗组65%。
- 中位无进展生存期:阿替利珠单抗组1.4个月(95%CI:1.2-1.5) vs 化疗组4.3个月(95%CI:1.5-5.9)。
- 中位总生存期:阿替利珠单抗组9.5个月 vs 化疗组8.7个月(校正HR 0.84,95%CI:0.45-1.58;P=0.60)。
- 53份可评估标本中仅1份(2%)免疫组化PD-L1染色阳性(SP142克隆)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This randomized phase II trial aimed at evaluating the engineered programmed cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line platinum-etoposide chemotherapy. METHODS: Patients were randomized 2:1 to atezolizumab (1200 mg intravenously every 3 weeks) until progression or unacceptable toxicity, or conventional chemotherapy (up to 6 cycles of topotecan or re-induction of initial chemotherapy). Patients were not selected based on PD-L1 tissue expression. The primary endpoint was objective response rate at 6 weeks. A two-stage design with 2:1 randomization and O'Brien-Fleming stopping rules was used. The null hypothesis was rejected if more than 12 of 45 patients were responders. RESULTS: Overall, 73 patients were randomized (atezolizumab n = 49; chemotherapy n = 24). At 6 weeks, 1 of 43 eligible atezolizumab patients achieved an objective response (2.3%, 95% confidence interval [CI]: 0.0-6.8), whereas 8 others had stable disease (20.9% disease control rate; 95% CI: 8.8-33.1). Among eligible chemotherapy patients (n = 20), 10% achieved an objective response (65% disease control rate). Median progression-free survival was 1.4 months (95% CI: 1.2-1.5) with atezolizumab and 4.3 months (95% CI: 1.5-5.9) with chemotherapy. Overall survival did not significantly differ between groups. Median overall survival was 9.5 months versus 8.7 months for the atezolizumab and the chemotherapy group, respectively (adjusted hazard ratioatezolizumab : 0.84, 95% CI: 0.45-1.58; p = 0.60). Two atezolizumab patients (4.2%) experienced grade 3 fatigue, and two others grade 1 dysthyroidism. Among 53 evaluable specimens, only 1 (2%) had positive immunohistochemical PD-L1 staining (SP142 clone). CONCLUSIONS: Atezolizumab monotherapy in relapsed SCLC failed to show significant efficacy. No unexpected safety concerns were observed.
引用
- Pujol JL, Greillier L, Audigier-Valette C, et al. A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial. J Thorac Oncol. 2019. PMID: 30664989. doi:10.1016/j.jtho.2019.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。